Novo Nordisk A/S Common Stock (NY:NVO)

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

Today 11:57 EST

On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the...

Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗

Today 9:59 EST

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch ↗

February 05, 2026

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

Today 4:10 EST

The stock has climbed in the triple digits over the past three years.

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA scrutiny.

Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit ↗

February 09, 2026

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? ↗

Topics Artificial Intelligence Lawsuit Stocks

February 09, 2026

Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.

These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue.

Topics Intellectual Property Lawsuit

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗

February 09, 2026

Novo Nordisk is suing Hims & Hers -- but Hims & Hers already surrendered.

Topics Intellectual Property

Why Novo Nordisk Stock Just Popped ↗

February 09, 2026

Everyone's ganging up on Hims & Hers stock this week.

Topics Intellectual Property Lawsuit

Why Hims & Hers Stock Just Got Destroyed ↗

February 09, 2026

The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash

Topics Lawsuit

February 09, 2026

The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to...

According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.

Topics Intellectual Property Lawsuit

FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains ↗

February 09, 2026

Novo Nordisk just did Eli Lilly stock a huge favor.

Topics Lawsuit

Why Eli Lilly Stock Just Popped ↗

February 09, 2026

The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn

Topics Lawsuit

February 09, 2026

The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of...

Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks ↗

Topics Earnings Intellectual Property

February 09, 2026

Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.

HIMS Stock In Turmoil: Retail Bulls Bet On Rebound, Skeptics See Bloodbath After Compounded Weight-Loss Pill Halt ↗

Topics Intellectual Property Lawsuit

February 08, 2026

Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight.

Novo Nordisk has good news and bad news to report in its fourth-quarter 2025 earnings.

Topics Intellectual Property Law Enforcement

Novo Nordisk Plunges Nearly 15% After Earnings. Here's What Investors Need to Know. ↗

February 08, 2026

Medicare Changes in 2026 Every Retiree Needs to Know: The Good, the Bad, and the Ugly ↗

February 08, 2026

Retirees should brace themselves for both positive and negative changes to Medicare this year.

Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.

Topics Economy Government Retirement

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 07, 2026

HIMS Stock Slumps After-Hours On Regulatory Scrutiny On Heels Of Compounded Wegovy Pill Launch ↗

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

February 06, 2026

The U.S. Food and Drugs Administration Commissioner Martin A Makary announced the agency’s intent to restrict the ingredients used by Hims as alternatives to FDA-approved drugs.

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...

The market for obesity drugs may soon reach almost $100 billion.

Topics Earnings Economy

Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore ↗

February 06, 2026

The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral...

The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market

February 06, 2026

The drugmaker is facing pricing pressures on its weight loss medications.

Topics Economy Intellectual Property Law Enforcement

Why Shares of Novo Nordisk Stock Collapsed This Week ↗

February 06, 2026

The Trillion-Dollar Divergence: Eli Lilly Hits Milestone While Novo Nordisk Faces 'Supply Chain Reset'

February 06, 2026

The global race for obesity market dominance reached a historic turning point this week as Eli Lilly and Company (NYSE: LLY) officially crossed the $1 trillion market capitalization threshold,...

The market is in an unforgiving mood.

Topics Economy

Why Did AMD, Uber, and Novo Nordisk Stock Crash This Week? ↗

February 06, 2026

As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade...

The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance

February 06, 2026

Via Finterra

Topics Economy Government Intellectual Property

Eli Lilly Stock Has Over 20% Upside, Analysts Say: Retail Seeks Pharma 'Safe Haven' As FDA Targets GLP-1 Copycats ↗

February 05, 2026

The stock’s rise followed FDA Commissioner Marty Makary's warning against companies marketing illegal copycat drugs.

Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗

Topics Fraud Law Enforcement

February 05, 2026

There's another fight brewing around GLP-1 drugs -- this time on the delivery side.